Targeted Stem Cell Exosome Therapy
Powered by 3D Bioreactor — 260 Disease-Specific Models
10+ Years Clinical Use in 9 Tier-1 Hospitals
Trusted by Leading Medical Institutions
Why Yanhua Bio Is Different
Generic exosomes are like giving the same medicine to 260 different diseases. We don’t do that.
| Conventional MSC Exosomes | Yanhua Targeted Exosomes | |
|---|---|---|
| Production Method | Standard 2D flat-plate culture | 3D bioreactor simulating disease microenvironment |
| Specificity | Generic — one product for all | Targeted — 260+ disease-specific formulations |
| Blood-Brain Barrier | Cannot cross | Nanoscale particles (50-200nm) can penetrate |
| Clinical Validation | Limited or no clinical data | 10+ years in 9 Tier-1 hospitals |
Three Products. Three Targets.
YanHua Vital
Systemic Wellness & Immune Modulation
Broad-spectrum cellular rejuvenation for overall health optimization.
- Anti-aging & cellular regeneration
- Sleep quality improvement
- Metabolic optimization
- Immune system regulation
YanHua Target
Disease-Specific Targeted Therapy
Precision exosomes engineered for specific conditions via 3D bioreactor.
- Neurological disorders (Parkinson’s, Alzheimer’s)
- Autoimmune conditions
- Cardiovascular repair
- Metabolic syndrome
YanHua Glow
Aesthetic & Regenerative Medicine
Type III collagen synthesis stimulation for skin rejuvenation and hair restoration.
- Skin rejuvenation & wrinkle reduction
- Hair growth stimulation
- Scar reduction
- Skin tone improvement
What Sets Us Apart
Precision Targeting
Disease-specific exosomes that home to target tissues with the right molecular cargo already loaded.
Beyond Single MSC
Not just MSC secretome — engineered with immune T-cells, NK cells, and interferons for enhanced therapeutic potential.
Proven in Hospitals
10+ years of clinical application across 9 Tier-1 hospitals in China with comprehensive patient data.
Full Cold Chain
2-8°C temperature monitoring with complete documentation from production to delivery.
Ready to Explore Partnership?
Join 9+ Tier-1 hospitals already using our targeted exosome therapy.